QIAGEN NV QGEN
NYSE · United States · Health Technology
$43.76-0.64 (-1.44%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company’s rapid sepsis testing portfolio in a single automated system. Qiagen’s latest FDA clearance lands after a period of mixed trading, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. Scan how Qiagen’s...
Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing gram-positive and fungal panel and expanding its syndromic infectious disease testing menu. This clearance materially broadens QIAGEN’s coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global magnetic beads market was valued at an estimated US$3.3 billion in 2025 and is projected to reach US$7.4 billion by 2032, advancing at a compound annual growth rate (CAG
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.